Literature DB >> 7658348

Percutaneous absorption and dermal delivery of cyclosporin A.

H K Choi1, G L Flynn, G L Amidon.   

Abstract

The present study deals with attempts to deliver cyclosporin A into the deeper skin and some of the fundamental reasons why this proves so difficult. Because of different physicochemical requirements for the solution and activity of cyclosporin A and the enhancer, n-decylmethyl sulfoxide, it was hard to demonstrate increases in permeation of cyclosporin A by the enhancer in either aqueous or ethanol/water formulation. Cyclosporin A was prohibitively insoluble in aqueous media and the activity of the enhancer is diminished to ineffectiveness when it is applied in alcoholic media. However, n-decylmethyl sulfoxide action on the stratum corneum could be obtained by pretreating the skin. The effect of pretreatment with this compound on the permeation of cyclosporin A through hairless mouse skin and human skin was studied with side-by-side diffusion cells. The skin was pretreated with 10 mM n-decylmethyl sulfoxide for various durations. Cyclosporin A in an ethanol/water formulation was then placed in the donor cell, with the amount of ethanol being controlled to maintain the highest possible thermodynamic activity. Accumulations of cyclosporin A in receiver cell media, aqueous or ethanol/water, were then assessed. Permeation from two different concentrations of cyclosporin A was compared. The permeability of hairless mouse skin to cyclosporin A was increased by the pretreatment, but results with human skin were more equivocal. It appears that it will take very long pretreatments to ready human skin for topical cyclosporin A therapy.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1995        PMID: 7658348     DOI: 10.1002/jps.2600840512

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  [Calcineurin inhibitors for topical therapy in psoriasis].

Authors:  J Wohlrab
Journal:  Hautarzt       Date:  2006-08       Impact factor: 0.751

2.  Ultraflexible lipid vesicles allow topical absorption of cyclosporin A.

Authors:  Juan J Carreras; Willian E Tapia-Ramirez; Adrian Sala; Antonio J Guillot; Teresa M Garrigues; Ana Melero
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 3.  A comprehensive review on possibilities of treating psoriasis using dermal cyclosporine.

Authors:  Sonia Pandey; Purnima Tripathi; Arti Gupta; Jitendra Singh Yadav
Journal:  Drug Deliv Transl Res       Date:  2021-09-22       Impact factor: 4.617

4.  Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles.

Authors:  Abderrazzaq Essaghraoui; Ahmed Belfkira; Bassou Hamdaoui; Cláudia Nunes; Sofia A Costa Lima; Salette Reis
Journal:  Nanomaterials (Basel)       Date:  2019-08-27       Impact factor: 5.076

5.  Viscosified Solid Lipidic Nanoparticles Based on Naringenin and Linolenic Acid for the Release of Cyclosporine A on the Skin.

Authors:  Sonia Trombino; Camilla Servidio; Annarita Stella Laganà; Filomena Conforti; Mariangela Marrelli; Roberta Cassano
Journal:  Molecules       Date:  2020-08-02       Impact factor: 4.411

6.  Enhanced Skin Delivery of Therapeutic Peptides Using Spicule-Based Topical Delivery Systems.

Authors:  Chi Zhang; Jiwen Duan; Yongxiang Huang; Ming Chen
Journal:  Pharmaceutics       Date:  2021-12-08       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.